Comprehensive analysis of hepatitis B virus infections in blood donors in southern China that are surface antigen positive but nucleic acid testing negative.
Journal
Transfusion
ISSN: 1537-2995
Titre abrégé: Transfusion
Pays: United States
ID NLM: 0417360
Informations de publication
Date de publication:
07 2020
07 2020
Historique:
received:
11
07
2019
revised:
11
03
2020
accepted:
13
03
2020
pubmed:
3
5
2020
medline:
23
6
2021
entrez:
3
5
2020
Statut:
ppublish
Résumé
Hepatitis B virus (HBV) infection is one of the major concerns for the safety of blood transfusion in high-prevalent countries such as in China. Prior studies outside of China have shown hepatitis B surface antigen (HBsAg) false-reactive rate of 0.02% to 0.04%. Similarly, false-negative HBsAg and HBV DNA results may occur in infected donors. Our study analyzed HBsAg enzyme-linked immunosorbent assay (ELISA)-reactive but NAT-negative donations in Shenzhen Blood Center, China. HBsAg ELISA-positive/NAT-negative plasma samples identified from screening 101,025 donations during 2017-2018 were analyzed by molecular and serologic tests including neutralization, chemiluminescence immunoassays, and various HBV DNA amplification assays. Molecular characterizations of HBsAg-positive/NAT-negative samples were determined by quantitative polymerase chain reaction (qPCR) and nested PCR amplification of the basic core and precore promotor regions (295 base pairs) and HBsAg (S) region (496 base pairs). Screening of 101,025 eligible blood donations identified 157 (0.16%, 95% confidence interval, 0.13%-0.18%) HBsAg ELISA-positive/NAT-negative plasma samples; of those, 71 (45.2%) were HBsAg confirmed positive by further HBsAg testing and DNA positive by molecular tests with increased sensitivity. Of the 71, all but one was antibody to hepatitis B core antigen reactive without antibody to hepatitis B surface antigen, yielding one recent (window-period) HBV infection. Of the remaining donations, 80 (51%) were not considered as HBV-infected donors, and 6 (3.8%) were interpreted as indeterminate since HBsAg results were discordant with unconfirmed HBV DNA results. In the 71 confirmed positives, HBsAg levels ranged from 0.05 to 400 IU/mL and HBV DNA from 6 to 2654 IU/mL; however, the correlation between the two was weak (R Fewer than half of HBsAg ELISA-positive/NAT-negative samples were confirmed as HBsAg positive. Our study demonstrates that in highly HBV-endemic countries, assays with high sensitivity and specificity may be required.
Sections du résumé
BACKGROUND
Hepatitis B virus (HBV) infection is one of the major concerns for the safety of blood transfusion in high-prevalent countries such as in China. Prior studies outside of China have shown hepatitis B surface antigen (HBsAg) false-reactive rate of 0.02% to 0.04%. Similarly, false-negative HBsAg and HBV DNA results may occur in infected donors. Our study analyzed HBsAg enzyme-linked immunosorbent assay (ELISA)-reactive but NAT-negative donations in Shenzhen Blood Center, China.
STUDY DESIGN AND METHODS
HBsAg ELISA-positive/NAT-negative plasma samples identified from screening 101,025 donations during 2017-2018 were analyzed by molecular and serologic tests including neutralization, chemiluminescence immunoassays, and various HBV DNA amplification assays. Molecular characterizations of HBsAg-positive/NAT-negative samples were determined by quantitative polymerase chain reaction (qPCR) and nested PCR amplification of the basic core and precore promotor regions (295 base pairs) and HBsAg (S) region (496 base pairs).
RESULTS
Screening of 101,025 eligible blood donations identified 157 (0.16%, 95% confidence interval, 0.13%-0.18%) HBsAg ELISA-positive/NAT-negative plasma samples; of those, 71 (45.2%) were HBsAg confirmed positive by further HBsAg testing and DNA positive by molecular tests with increased sensitivity. Of the 71, all but one was antibody to hepatitis B core antigen reactive without antibody to hepatitis B surface antigen, yielding one recent (window-period) HBV infection. Of the remaining donations, 80 (51%) were not considered as HBV-infected donors, and 6 (3.8%) were interpreted as indeterminate since HBsAg results were discordant with unconfirmed HBV DNA results. In the 71 confirmed positives, HBsAg levels ranged from 0.05 to 400 IU/mL and HBV DNA from 6 to 2654 IU/mL; however, the correlation between the two was weak (R
CONCLUSION
Fewer than half of HBsAg ELISA-positive/NAT-negative samples were confirmed as HBsAg positive. Our study demonstrates that in highly HBV-endemic countries, assays with high sensitivity and specificity may be required.
Substances chimiques
DNA, Viral
0
Hepatitis B Surface Antigens
0
Types de publication
Clinical Trial
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1476-1482Subventions
Organisme : the Beijing Science and Technology Commission to SW
ID : Z161100000516148
Organisme : the CAMS Initiative for Innovative Medicine
ID : CAMS-2016-I2M-3-025 2017-I2M-B&R-15
Organisme : the Health and Family Planning Commission of Shenzhen Municipality Foundation of China to XY
ID : SZGW2017018
Organisme : the National Key Research and Development Program from Ministry of Science and Technology of China
ID : 2018YFE0107500 to L.C
Organisme : the Science and Technology Partnership Program, Ministry of Science and Technology of China to LC
ID : KY201904011
Organisme : National Key Research and Development Program from Ministry of Science and Technology of China
ID : 2018YFE0107500
Organisme : CAMS Initiative for Innovative Medicine
ID : 2017-I2M-B&R-15
Organisme : CAMS Initiative for Innovative Medicine
ID : CAMS-2016-I2M-3-025
Informations de copyright
© 2020 AABB.
Références
WHO. Hepatitis B factsheet. Available from: http://www.who.int/mediacentre/factsheets/fs204/en/2017.
Song Y, Bian Y, Petzold M, et al. Prevalence and trend of major transfusion-transmissible infections among blood donors in Western China, 2005 through 2010. PLoS One 2014;9:e94528.
Servant-Delmas A, Mercier-Darty M, Ly TD, et al. Variable capacity of 13 hepatitis B virus surface antigen assays for the detection of HBsAg mutants in blood samples. J Clin Virol 2012;53:338-45.
Hollinger FB. Hepatitis B virus genetic diversity and its impact on diagnostic assays. J Viral Hepat 2007;14(Suppl 1):11-5.
El Chaar M, Candotti D, Crowther RA, et al. Impact of hepatitis B virus surface protein mutations on the diagnosis of occult hepatitis B virus infection. Hepatology 2010;52:1600-10.
Kiely P, Stewart Y, Castro L. Analysis of voluntary blood donors with biologic false reactivity on chemiluminescent immunoassays and implications for donor management. Transfusion 2003;43:584-90.
Ye X, Li T, Xu X, et al. Characterisation and follow-up study of occult hepatitis B virus infection in anti-HBc-positive qualified blood donors in southern China. Blood Transfus 2017;15:6-12.
Enjalbert F, Krysztof DE, Candotti D, et al. Comparison of seven hepatitis B virus (HBV) nucleic acid testing assays in selected samples with discrepant HBV marker results from United States blood donors. Transfusion 2014;54:2485-95.
Candotti D, Opare-Sem O, Rezvan H, et al. Molecular and serological characterization of hepatitis B virusin deferred Ghanaian blood donors with and without elevated alanine amino transferase. J Viral Hepat 2006;13:715-24.
Allain JP, Candotti D, Soldan K, et al. The risk of hepatitis B virus infection by transfusion in Kumasi, Ghana. Blood 2003;101:2419-25.
Candotti D, Laperche S. Hepatitis B virus blood screening: need for reappraisal of blood safety measures? Front Med (Lausanne) 2018;5:29-34.
Lelie N, Bruhn R, Busch M, et al. Detection of different categories of hepatitis B virus (HBV) infection in a multi-regional study comparing the clinical sensitivity of hepatitis B surface antigen and HBV-DNA testing. Transfusion 2017;57:24-35.
Dodd RY, Nguyen ML, Krysztof DE, et al. Blood donor testing for hepatitis B virus in the United States: is there a case for continuation of hepatitis B surface antigen detection? Transfusion 2018;58:2166-70.
Roth WK, Busch MP, Schuller A, et al. International survey on NAT testing of blood donations: expanding implementation and yield from 1999 to 2009. Vox Sang 2012;102:82-90.
Stramer SL, Krysztof DE, Brodsky JP, et al. Comparative analysis of triplex nucleic acid test assays in United States blood donors. Transfusion 2013;53:2525-37.
Grabarczyk P, van Drimmelen H, Kopacz A, et al. Head-to-head comparison of two transcription-mediated amplification assay versions for detection of hepatitis B virus, hepatitis C virus, and human immunodeficiency virus type 1 in blood donors. Transfusion 2013;53:2512-24.
Taira R, Satake M, Momose S, et al. Residual risk of transfusion-transmitted hepatitis B virus (HBV) infection caused by blood components derived from donors with occult HBV infection in Japan. Transfusion 2013;53:1393-404.
Seed CR, Maloney R, Kiely P, et al. Infectivity of blood components from donors with occult hepatitis B infection - results from an Australian lookback programme. Vox Sang 2015;108:113-22.
Weusten J, van Drimmelen H, Vermeulen M, et al. A mathematical model for estimating residual transmission risk of occult hepatitis B virus infection with different blood safety scenarios. Transfusion 2017;57:841-9.
Vo MT, Bruhn R, Kaidarova Z, et al. A retrospective analysis of false-positive infectious screening results in blood donors. Transfusion 2016;56:457-65.
Dow BC, Yates P, Galea G, et al. Hepatitis B vaccinees may be mistaken for confirmed hepatitis B surface antigen-positive blood donors. Vox Sang 2002;82:15-7.
Zhu HY, Zhang XS. Relationship between HBV DNA load and levels of serum HBsAg in patients with chronic hepatitis B. Eur Rev Med Pharmacol Sci 2016;20:2061-4.
Sato S, Ohhashi W, Ihara H, et al. Comparison of the sensitivity of NAT using pooled donor samples for HBV and that of a serologic HBsAg assay. Transfusion 2001;41:1107-13.
Biswas R, Tabor E, Hsia CC, et al. Comparative sensitivity of HBV NATs and HBsAg assays for detection of acute HBV infection. Transfusion 2003;43:788-98.
Kuhns MC, Kleinman SH, McNamara AL, et al. Lack of correlation between HBsAg and HBV DNA levels in blood donors who test positive for HBsAg and anti-HBc: implications for future HBV screening policy. Transfusion 2004;44:1332-9.
Pollicino T, Amaddeo G, Restuccia A, et al. Impact of hepatitis B virus (HBV) preS/S genomic variability on HBV surface antigen and HBV DNA serum levels. Hepatology 2012;56:434-43.
Liu MH, Chen QY, Harrison TJ, et al. The correlation between serum HBsAg levels and viral loads depends upon wild-type and mutated HBV sequences rather than the HBeAg/anti-HBe status. J Med Virol 2015;87:1351-60.